Posters

      Lung Function In A/J Mice Following Subchronic Cigarette Smoke Exposure - Patterns Of Emphysematous And Fibrotic Changes

      Pype, J. L.; Van Miert, E.; Meurrens, K. T.; Peck, M.; Vanscheeuwijck, P. M.
      Conference date
      Jun 28, 2006
      Conference name
      5th International Multidisciplinary Meeting On Chronic Obstructive Pulmonary Disease
      Link to more information
      Link to more information
      Topic
      Summary

      Airflow limitation due to small airway diseases and emphysema is a defining feature of COPD. We investigated lung function in female A/J mice exposed to fresh air or MS from the reference cigarette 2R4F for 2, 3, or 4 x 1 hour/day, 5 days/week at 750 µg total particulate matter (TPM)/L for 3 and 5 months. Respiratory mechanics were determined in anesthetized mice (10/group) using a computer-controlled small animal ventilator (Flexivent). At 3 months, no significant increase in tissue elastance (HTIS) was found, while at 5 months HTIS was significantly increased at all smoke doses (14.6±1.2, 19.1±5.9, 18.9±2.0 and 19.4±1.8 for 0, 1500, 2250, and 3000 µg TPM/(L x day), respectively. For all MS-exposed mice at 3 and 5 months, maximal lung volume (at 30 cm H2O) was significantly increased (30.3±3.2 vs 58.5±4.2 ml/Kg, Sham vs 3000 µg TPM/(L x day) group at 5 months) and the maximal airway pressure at total lung capacity was significantly decreased (40.4.±4.4 vs 24.9±4.1 cm H2O, sham vs 3000 µg TPM/(L x day) group at 5 months). Subchronic MS exposure in A/J mice resulted in time- and dose-dependent changes in lung function parameters, similar to changes observed in bleomycin (fibrosis)- and elastase (emphysema)-treated mice. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.